(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
EU agrees on agriculture safeguards as fronts harden in Mercosur deal - 2US FDA unveils new pathway to approve personalized therapies
- 3Uzbekistan launches €9.46 billion green energy push, covering nation’s power needs
- 4Scientists find twisting magnetic waves on the sun. Could this help solve a huge solar mystery?
- 5Best Exciting ride: Which One Rushes You the Most?
- Over 250,000 cases of shredded cheese recalled over possible metal fragments
- IDF bans Android phones for senior officers, iPhones now mandatory, Army Radio reports
- Relish the World: Notable Caf\u00e9s You Really want to Attempt
- Newly Built Sichuan Hydropower Bridge Collapses Into River Months After Opening
- The Way to Recuperation: Defeating Dependence
- Israel's haredi draft crisis: Court ruling and political stalemate reach breaking point
- Palestinian infant freezes to death in Gaza as Israel keeps blocking aid
- Really focusing on Succulents: Tips and Procedures
- Hezbollah claims right to respond to killing of top commander
